NPS Pharmaceuticals Inc (NPSP)

45.97
0.01 0.02
Prev Close 45.96
Open 45.96
Day Low/High 45.95 / 45.99
52 Wk Low/High 22.11 / 46.01
Volume 9.49M
Avg Volume 4.75M
Exchange
Shares Outstanding 108.58M
Market Cap 4.99B
EPS -0.08
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

Amid much volatility, earnings season wrapped up this week and we added to three model portfolio names and trimmed one other.

Reviewing the Numbers

This pharmaceutical name delivered mixed quarterly results, but its two lead products remain on track for FDA approval.

NPS Pharmaceuticals Reports Third Quarter 2012 Financial Results And Reiterates Year-end Cash Guidance

NPS Pharmaceuticals Reports Third Quarter 2012 Financial Results And Reiterates Year-end Cash Guidance

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for the third quarter of 2012.

Presenting a Trio of Previews

Here's what we'll be listening for when these three model portfolio names report their quarterly earnings on Friday.

NPS Pharmaceuticals To Present At Upcoming Healthcare Conferences

NPS Pharmaceuticals To Present At Upcoming Healthcare Conferences

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the Lazard Capital Markets 9 th Annual Healthcare Conference in New York on Wednesday, November 14, 2012 at 9:30 a.

NPS Pharmaceuticals To Report Third Quarter 2012 Financial Results

NPS Pharmaceuticals To Report Third Quarter 2012 Financial Results

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will issue its third quarter 2012 financial release on Friday, November 9, 2012 at approximately 8:00 a.

21 Most Volatile Biopharma Stocks Closing Out 2012

21 Most Volatile Biopharma Stocks Closing Out 2012

These biopharma firms will be announcing FDA drug approval decisions and important clinical trial results.

Stocks Under $10 Weekly Summary

During this shortened trading week, several model portfolio names reported earnings and we used the volatility to make four trades.

Stocks Under $10 Weekly Summary

With earnings season in full swing, we used the volatility this week to add to two of our model portfolio positions.

Stocks Under $5: Blossoming Biotech Play

Stocks Under $5: Blossoming Biotech Play

Portfolio manager David Peltier discusses how to play one the most volatile low-dollar stocks of 2012.

Cramer's Top Stock Picks: JAH FB NPSP

Cramer's Top Stock Picks: JAH FB NPSP

Cramer likes Jarden's commitment to shareholders, NPS' innovation and Facebook getting its act together.

Cramer's 'Mad Money' Recap: Looking for Winners

Cramer's 'Mad Money' Recap: Looking for Winners

They're out there, Cramer said, and they have one thing in common -- great execution.

NPS Pharmaceuticals Reports Characteristics Of Patients Who Achieved Independence From Parenteral Support In STEPS 2 Study Of Gattex® (teduglutide) In Adult Short Bowel Syndrome

NPS Pharmaceuticals Reports Characteristics Of Patients Who Achieved Independence From Parenteral Support In STEPS 2 Study Of Gattex® (teduglutide) In Adult Short Bowel Syndrome

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported data related to the seven patients who...

Stocks Under $10 Weekly Summary

At the end of this week, we took advantage of the downturn in the major averages to add to four model portfolio positions.

A Trio of Trades

We are taking advantage of today's sharp selloff in the broader market averages to add shares to three of our holdings.

Stocks Under $5: Live Twitter Chat

Stocks Under $5: Live Twitter Chat

Join Portfolio Mgr. David Peltier @davidspeltier on Twitter Thursday at 4:30 pm ET, for his #SU10chat

Update for a Pharmaceutical Name

The shares are experiencing a sell-the-news reaction after the FDA issued a favorable opinion on one of its drugs on Tuesday.

FDA Advisory Committee Unanimously Recommends Approval Of Gattex® (teduglutide) For Adults With Short Bowel Syndrome (SBS)

FDA Advisory Committee Unanimously Recommends Approval Of Gattex® (teduglutide) For Adults With Short Bowel Syndrome (SBS)

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today that the U.

NPS Pharma FDA Panel Live Blog

NPS Pharma FDA Panel Live Blog

An FDA panel weighs the risk and benefits of NPS Pharma's Gattex.

NPS Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee To Review Gattex® New Drug Application For The Treatment Of Adults With Short Bowel Syndrome

NPS Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee To Review Gattex® New Drug Application For The Treatment Of Adults With Short Bowel Syndrome

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that NASDAQ has halted trading of the...

New Data From REPLACE Study Show Initiation Of Bone Remodeling For Natpara®-Treated Patients With Hypoparathyroidism

New Data From REPLACE Study Show Initiation Of Bone Remodeling For Natpara®-Treated Patients With Hypoparathyroidism

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today new findings from the double-blind, ...

3 Biotech Stocks Facing Crucial FDA Advisory Panels This Week

3 Biotech Stocks Facing Crucial FDA Advisory Panels This Week

NPS Pharma, Aegerion and Isis Pharma all bring drugs in front of FDA advisory panels this week.

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer's 'Mad Money' Recap: Next Week's Game Plan

It's a busy week for earnings, Cramer said, and investors need to stop, look and listen before they buy.

Stocks Under $10 Weekly Summary

It was a quiet week for the model portfolio but our first name is scheduled to report its quarterly earnings next week.

Good News for a Pharmaceuticals Name

The FDA published briefing documents that raise the probability that one of the company's drugs will be approved.

FDA Posts Briefing Documents For Advisory Committee Meeting Reviewing Gattex® (teduglutide) For Adult Short Bowel Syndrome

FDA Posts Briefing Documents For Advisory Committee Meeting Reviewing Gattex® (teduglutide) For Adult Short Bowel Syndrome

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today that the U.

Cramer's 'Mad Money' Recap: The Great Divide

Cramer's 'Mad Money' Recap: The Great Divide

Every day the bulls and the bears are duking it out to win the hearts and minds of investors, Cramer said.

NPS Pharma: Gattex FDA Panel Preview

NPS Pharma: Gattex FDA Panel Preview

NPS Pharma faces a key regulatory test of its short-bowel syndrome drug on Oct. 16.

NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel

NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel

Biotech options expert Tony Pelz recommends a bullish options trade for the Oct. 16 Gattex FDA panel.

Stocks Under $10 Weekly Summary

In a volatile trading week, we added to two positions to the model portfolio and booked a substantial gain in another.